Scientific work

Prof. Dr. Marıa Del Pılar Laguna Pes

491 publications. The source of the information is stated next to each publication.

Back to profile

  1. 279. P.J. Zondervan, P.G. Wagstaff, M.M. Desai, D.M. de Bruin, A.F. Fraga, B.A. Hadaschik, J. Köllermann, U.B. Liehr, S.A. Pahernik, H.P. Schlemmer, J.J. Wendler, F. Algaba, J.J.M.C.H. de la Rosette, M.P. Laguna Pes. Follow-up after focal therapy in renal masses: an international multidisciplinary Delphi consensus project. World J Urol. 2016 Apr 22.

    Source: medipol.com.tr profile page

  2. 280. W. van den Bos, R.R. Jurhill, D.M. de Bruin, C.D. Savci-Heijink, A.W. Postema, P.G. Wagstaff, B.G. Muller, I.M. Varkarakis, A. Skolarikos, P.J. Zondervan, M.P. Laguna Pes, Th.M. de Reijke, J.J.M.C.H. de la Rosette. Histopathological Outcomes after Irreversible Electroporation in Prostate Cancer: Results of an Ablate and Resect Study. J Urol. 2016 Mar 19. pii: S0022-5347(16)03679-X.

    Source: medipol.com.tr profile page

  3. 281. P.J. Zondervan, K.P. van Lienden, O.M. van Delden, J.J.M.C.H. de la Rosette, M.P. Laguna Pes. Preoperative Decision Making for Nephron-Sparing Procedure in the Renal Mass: Time for Using Standard Tools? J Endourol. 2016 Jan;30(1):128-34.

    Source: medipol.com.tr profile page

  4. 282. M.P. Laguna Pes. Re: Genomic Characterization of Upper Tract Urothelial Carcinoma. JUrol. 2016 Jun;195(6):1719. doi: 10.1016/j.juro.2016.03.029. Epub 2016 Mar 18. PubMed PMID: 27191062.

    Source: medipol.com.tr profile page

  5. 283. M.P. Laguna Pes. Re: Prospective Evaluation of(99m)Tc-Sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors. J Urol. 2016 Jun;195(6):1718-9.

    Source: medipol.com.tr profile page

  6. 284. M.P. Laguna Pes. Re: Renal Tumor Biopsy for Small Renal Masses: A Single-Center 13-Year Experience. J Urol. 2016 May;195(5):1378-9.

    Source: medipol.com.tr profile page

  7. 285. M.P. Laguna Pes. Re: Partial vs Radical Nephrectomy for T1 Renal Tumours: An Analysis from the British Association of Urological Surgeons Nephrectomy Audit. J Urol. 2016 May;195(5):1377-9.

    Source: medipol.com.tr profile page

  8. 286. J. Rioja, E. Morcillo, J.P. Novalbos, M.A. Sánchez, F. Soria, F. Pérez, I. Diaz-Güemes, M.P. Laguna Pes, F.M. Sanchez-Margallo, F.R. Cortadellas. Laparoscopic Partial Nephrectomy with KTP Laser Versus Conventional Laparoscopic Partial Nephrectomy: an Animal Randomized Controlled Trial. Urology. 2016 Apr 21. pii: S0090-4295(16)30093-0.

    Source: medipol.com.tr profile page

  9. 287. A. Garde, L. Sörnmo, M.P. Laguna Pes, R. Jané, S. Benito, A. Bayés-Genís, B.F. Giraldo. Assessment of respiratory flow cycle morphology in patients with chronic heart failure. Med Biol Eng Comput. 2016 Apr 23.

    Source: medipol.com.tr profile page

  10. 288. O. Barquero-Perez, C. Figuera, R. Goya-Esteban, I. Mora-Jimenez, F.J. Gimeno-Blanes, M.P. Laguna Pes, J.P. Martinez Cortes, E. Gil, L. Sornmo, A. Garcia-Alberola, J.L. Rojo-Alvarez. On the Influence of Heart Rate and Coupling Interval Prematurity on Heart Rate Turbulence. IEEE Trans Biomed Eng. 2016 Apr 15.

    Source: medipol.com.tr profile page

  11. 289. G. Gakis, T. Schubert, M. Alemozaffar, J. Bellmunt, B.H. Bochner, S.A. Boorjian, S. Daneshmand, W.C. Huang, T. Kondo, B.R. Konety , M.P. Laguna Pes, S.F. Matin, A.O. Siefker-Radtke, S.F. Shariat, A. Stenzl. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World JUrol. 2016 Apr 4.

    Source: medipol.com.tr profile page

  12. 290. M.P. Laguna Pes. Re: Clinical and Radiographic Predictors of the Need for Inferior Vena Cava Resection during Nephrectomy for Patients with Renal Cell Carcinoma and Caval Tumour Thrombus. J Urol. 2016 Mar;195(3):609.

    Source: medipol.com.tr profile page

  13. 291. P.J. Zondervan, M. Buijs, J.J.M.C.H. de la Rosette, O. van Delden, K. van Lienden, M.P. Laguna Pes. Cryoablation of small kidney tumors. Int J Surg. 2016 Aug 5. pii:S1743-9191(16)30286-2.

    Source: medipol.com.tr profile page

  14. 292. M.T. Bus, D.M. de Bruin, D.J. Faber, G.M. Kamphuis, P.J. Zondervan, M.P. Laguna Pes, T.G. van Leeuwen, Th.M. de Reijke, J.J.M.C.H. de la Rosette. Optical Coherence Tomography as a Tool for in Vivo Staging and Grading of Upper Urinary Tract Urothelial Carcinoma: A Study for Diagnostic Accuracy. J Urol. 2016 Jul 27. pii: S0022-5347(16)30924-.

    Source: medipol.com.tr profile page

  15. 293. M.J. Scheltema, W. van den Bos, P.G. Wagstaff, A.W. Postema, D.M. de Bruin, M.P. Laguna Pes, J.J.M.C.H. de la Rosette. Irreversible electroporation, a new modality in Focal Therapy for prostate cancer. Arch Esp Urol. 2016 Jul;69(6):337-44.

    Source: medipol.com.tr profile page

  16. 294. P.G. Wagstaff, M. Buijs, W. van den Bos, D.M. de Bruin, P.J. Zondervan, J.J.M.C.H. de la Rosette, M.P. Laguna Pes. Irreversible electroporation: state of the art. Onco Targets Ther. 2016 Apr 22;9:2437-46.

    Source: medipol.com.tr profile page

  17. 295. W. van den Bos, D.M. de Bruin, A. van Randen, M.R. Engelbrecht, A.W. Postema, B.G. Muller, I.M Varkarakis, A. Skolarikos, C.C. Savci-Heijink, R.R. Jurhill, P.J. Zondervan, M.P. Laguna Pes, H. Wijkstra, Th.M. de Reijke, J.J.M.C.H. de la Rosette. MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy. Eur Radiol. 2016 Jul;26(7):2252-60.

    Source: medipol.com.tr profile page

  18. 296. W. van den Bos, D.M. de Bruin, R.R. Jurhill, C.D. Savci-Heijink, B.G. Muller, I.M. Varkarakis, A. Skolarikos, P.J. Zondervan, M.P. Laguna Pes, H. Wijkstra, Th.M. de Reijke, de la Rosette JJ. The correlation between the electrode configuration and histopathology of irreversible electroporation ablations in prostate cancer patients. World J Urol. 2016 May;34(5):657-64.

    Source: medipol.com.tr profile page

  19. 297. M.P. Laguna Pes. Re: The Subclassification of Papillary Renal Cell Carcinoma Does Not Affect Oncological Outcomes after Nephron Sparing Surgery. J Urol. 2016 Sep;196(3):686-7.

    Source: medipol.com.tr profile page

  20. 298. M.P. Laguna Pes. Re: Prediction of Complications following Partial Nephrectomy: Implications for Ablative Techniques Candidates. J Urol. 2016 Sep;196(3):685-7.

    Source: medipol.com.tr profile page

  21. 299. M.P. Laguna Pes. Re: Prediction of Pulmonary Metastasis in Renal Cell Carcinoma Patients with Indeterminate Pulmonary Nodules. J Urol. 2016 Aug;196(2):350.

    Source: medipol.com.tr profile page

  22. 300. M.P. Laguna Pes. Re: Guideline of Guidelines: Follow-up after Nephrectomy for Renal Cell Carcinoma. J Urol. 2016 Aug;196(2):349-50.

    Source: medipol.com.tr profile page

  23. 301. M.P. Laguna Pes. Re: Oncologic Surveillance after Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach. J Urol. 2016 Jul;196(1):58-9.

    Source: medipol.com.tr profile page

  24. 302. M.P. Laguna Pes. Re: Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy. J Urol. 2016 Jul;196(1):57-9.

    Source: medipol.com.tr profile page

  25. 303. M.P. Laguna Pes. Re: Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. J Urol. 2016 Apr;195(4P1):900-1.

    Source: medipol.com.tr profile page

  26. 304. M.P. Laguna Pes. Re: Genomic Characterization of Upper Tract Urothelial Carcinoma. J Urol. 2016 Jun;195(6):1719.

    Source: medipol.com.tr profile page

  27. 305. M.P. Laguna Pes. Re: Prospective Evaluation of(99m)Tc-Sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors. J Urol. 2016 Jun;195(6):1718-9.

    Source: medipol.com.tr profile page

  28. 306. M.P. Laguna Pes. Re: Renal Tumor Biopsy for Small Renal Masses: A Single-Center 13-Year Experience. J Urol. 2016 May;195(5):1378-9.

    Source: medipol.com.tr profile page

  29. 307. M.P. Laguna Pes. Re: Partial vs Radical Nephrectomy for T1 Renal Tumours: An Analysis from the British Association of Urological Surgeons Nephrectomy Audit. J Urol. 2016 May;195(5):1377-9.

    Source: medipol.com.tr profile page

  30. 308. M.P. Laguna Pes. Re: Clinical and Radiographic Predictors of the Need for Inferior Vena Cava Resection during Nephrectomy for Patients with Renal Cell Carcinoma and Caval Tumour Thrombus. J Urol. 2016 Mar;195(3):609.

    Source: medipol.com.tr profile page

  31. 309. M.P. Laguna Pes. Re: Health Economic Changes as a Result of Implementation of Targeted Therapy for Metastatic Renal Cell Carcinoma: National Results from DARENCA Study 2. J Urol. 2016 Mar;195(3):608.

    Source: medipol.com.tr profile page

  32. 310. M.P. Laguna Pes. Re: Trifecta and Optimal Perioperative Outcomes of Robotic and Laparoscopic Partial Nephrectomy in Surgical Treatment of Small Renal Masses: A Multi-Institutional Study. J Urol. 2016 Feb;195(2):298.

    Source: medipol.com.tr profile page

  33. 311. M.P. Laguna Pes. Re: Novel Kidney Segmentation System to Describe Tumour Location for Nephron-Sparing Surgery. J Urol. 2016 Jan;195(1):61.

    Source: medipol.com.tr profile page

  34. 312. M.P. Laguna Pes. Re: Interobserver Variability of R.E.N.A.L., PADUA, and Centrality Index Nephrometry Score Systems. J Urol. 2016 Jan;195(1):60-1.

    Source: medipol.com.tr profile page

  35. 313. M.P. Laguna Pes. Re: Change in Neutrophil-to-Lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. J Urol. 2016 Dec;196(6):1634-1635.

    Source: medipol.com.tr profile page

  36. 314. M.P. Laguna Pes. Re: Nephron-Sparing Surgery across a Nation-Outcomes from the British Association of Urological Surgeons 2012 National Partial Nephrectomy Audit. J Urol. 2016 Dec;196(6):1635.

    Source: medipol.com.tr profile page

  37. 315. M.P. Laguna Pes. Re: Five-Year Oncologic Outcomes after Transperitoneal Robotic Partial Nephrectomy for Renal Cell Carcinoma. J Urol. 2016 Nov;196(5):1398.

    Source: medipol.com.tr profile page

  38. 316. M.P. Laguna Pes. Re: Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs >4cm can be Offered Active Surveillance as an Initial Management Strategy. J Urol. 2016 Nov;196(5):1397-1398

    Source: medipol.com.tr profile page

  39. 317. J.H. Jaunarena, C. Cristallo, M.S. González, F.P. Daels, J.J.M.C.H. De la Rosette, M.P. Laguna Pes. [Management of malignant ureteral obstruction.]. Arch Esp Urol. 2016 Oct;69(8):507-517. Spanish.

    Source: medipol.com.tr profile page

  40. 318. M.P. Laguna Pes. Re: Cystic Renal Cell Carcinoma Carries an Excellent Prognosis Regardless of Tumor Size. J Urol. 2016 Oct;196(4):1042-3.

    Source: medipol.com.tr profile page

  41. 319. M.P. Laguna Pes. Re: The Subclassification of Papillary Renal Cell Carcinoma Does Not Affect Oncological Outcomes after Nephron Sparing Surgery. J Urol. 2016 Sep;196(3):686-7.

    Source: medipol.com.tr profile page

  42. 320. M.J. Scheltema, K.J. Tay, A.W. Postema, D.M. de Bruin, J. Feller, J.J. Futterer, A.K. George, R.T. Gupta, F. Kahmann, C. Kastner, M.P. Laguna Pes, S. Natarajan, S. Rais-Bahrami, A.R. Rastinehad, T.M. de Reijke, G. Salomon, N. Stone, R. van Velthoven, R. Villani, A. Villers, J. Walz, T.J. Polascik, J.J.M.C.H. de la Rosette. Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project. World J Urol.2017 ;35(5):695-701.

    Source: medipol.com.tr profile page

  43. 321. G. Gakis, T. Schubert , M. Alemozaffar, J. Bellmunt, B.H. Bochner, S.A. Boorjian, S. Daneshmand, W.C. Huang, T. Kondo, B.R. Konety, M.P. Laguna Pes, S.F. Matin, A.O. Siefker-Radtke, S.F. Shariat, A. Stenzl. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World J Urol. 2017 Mar;35(3):327-335.

    Source: medipol.com.tr profile page

  44. 322. M.T. Bus, D.M. de Bruin, G.M. Kamphuis, P.J. Zondervan, M.P. Laguna Pes, Th.M. de Reijke, T.G. van Leeuwen, J.J.M.C.H. de la Rosette. Current position of diagnostics and surgical treatment for upper tract urothelial carcinoma. Minerva Urol Nefrol. 2017 Apr;69(2):159-165.

    Source: medipol.com.tr profile page

  45. 324. A. Ingels, M. Hew, F. Algaba, O.J. de Boer, R.J. van Moorselaar, S. Horenblas, P. Zondervan, J.J.M.C.H. de la Rosette, M.P. Laguna Pes. Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study. World J Urol. 2017 Jan;35(1):81-87.

    Source: medipol.com.tr profile page

  46. 326. M.P. Laguna Pes Re: Clinically Localized Type 1 and 2 Papillary Renal Cell Carcinomas Have Similar Survival Outcomes following Surgery. J Urol. 2017 Jan;197(1):50-51.

    Source: medipol.com.tr profile page

  47. 327. M. Smeenge, F. Tranquart, C.K. Mannaerts, Th. M. de Reijke, M.J. van de Vijver, M.P. Laguna Pes, S. Pochon, J.J.M.C.H. de la Rosette, H. Wijkstra. First-in-Human Ultrasound Molecular Imaging With a VEGFR2-Specific Ultrasound Molecular Contrast Agent (BR55) in Prostate Cancer: A Safety and Feasibility Pilot Study. Invest Radiol. 2017 Jul;52(7):419-427.

    Source: medipol.com.tr profile page

  48. 328. J. Baard, D.M de Bruin, P.J Zondervan, G. Kamphuis, J.J.M.C.H. de la Rosette, M.P. Laguna Pes. Diagnostic dilemmas in patients with upper tract urothelial carcinoma. Nature Review; Urol. 2017 Mar;14(3):181-191.

    Source: medipol.com.tr profile page

  49. 329. M.P. Laguna Pes. Re: Population-Based Assessment of Cancer-Specific Mortality after

    Source: medipol.com.tr profile page

  50. Local Tumour Ablation or Observation for Kidney Cancer: A Competing Risks

    Source: medipol.com.tr profile page